MKNK2

Across TCGA pan-cancer cohorts, MKNK2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MKNK2 data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher MKNK2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MKNK2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

HNSC, PDAC, and LSCC are the cancer types where MKNK2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	III,IV	0.942	0.621	.002	32	view →
PDAC	OS	Tertile	II,III,IV	0.258	0.999	.024	14	view →
LSCC	DFS	Quartile	All	1.000	0.473	.040	3	view →
LUAD	DFS	Median	II,III,IV	0.869	0.244	.007	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MKNK2–HNSC (DFS)

Open the HNSC breakdown →